A decade of immune-checkpoint inhibitors in cancer therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32732879.
- Also identified by DOI 10.1038/s41467-020-17670-y and PMC identifier 7393098.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Medical subject headings
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- CTLA-4 Antigen
- Immunotherapy
- Neoplasms
- Programmed Cell Death 1 Receptor